Kevin O'Reilly
Psychiatric/Mental Health · Maryville, TNNPI 1396229811
Payments from drug & device makers
Across 139 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$495
- AbbVie$475
- Alkermes, Inc.$342
- Takeda Pharmaceuticals U.S.A., Inc.$256
- Axsome Therapeutics, Inc.$233
- Vanda Pharmaceuticals Inc.$207
- plus $1K from 9 others
What the payments were for
- Food & beverage$3,125100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 19 | $495 |
| AbbVie | 24 | $475 |
| Alkermes, Inc. | 17 | $342 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $256 |
| Axsome Therapeutics, Inc. | 12 | $233 |
| Vanda Pharmaceuticals Inc. | 6 | $207 |
| Lundbeck LLC | 10 | $199 |
| Johnson & Johnson | 7 | $181 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $170 |
| Otsuka America Pharmaceutical, Inc. | 9 | $163 |
| Teva Pharmaceuticals USA, Inc. | 7 | $160 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| Averitas Pharma Inc. | 1 | $75 |
| Tris Pharma Inc | 3 | $59 |
| Bausch Health US, LLC | 1 | $18 |
How this compares
$3,125 in reported general payments places this provider in the 80th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 42 | $2,855 |
| Quetiapine Fumarate | 62 | $1,370 |
| Duloxetine Hcl | 25 | $759 |
| Bupropion XlBupropion Hcl | 35 | $697 |
| Mirtazapine | 40 | $488 |
| Lamotrigine | 26 | $452 |
| Buspirone Hcl | 19 | $403 |
| Sertraline Hcl | 39 | $385 |
| Hydroxyzine Pamoate | 26 | $338 |
| Trazodone Hcl | 30 | $312 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 11 | $244 |
| Olanzapine | 13 | $238 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $237 |
| Fluoxetine Hcl | 38 | $236 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $209 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Maryville
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
- Mary AllenMemphis$422K
- Lauren HansenNashville$263K
- Joshua ThompsonChattanooga$262K
- Kristal HurstBlaine$260K
- Kaitlynn EarlsGreeneville$228K
- Tory WoodardCookeville$191K
- Sarah VogelfangerMemphis$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.